COVID-19 Drug Repurposing Evaluation
(PK Prediction)

The drug repurposing for COVID-19 is evaluated as aspect of prediction of human pharmacokinetics in comparison with IC50. This study is done by CNU, KRIBB and KISTI (2021). The candidate drugs close to COVID-19 are extracted by machine learning. If you want to know about the whole drug list of Disease Drug Protein Potential Relationship based on machine learning analysis, see this page.

The 9 Drugs Evaluation

Covid-19
Drug

The re-creation of drugs for the Covid-19 is evaluated as aspect of IC50 vs Predicted Human PK.

Remdesivir

	Human Prediction PK	IC50 in Vero cell	IC50 in Calu-3 cell
Cmax	4.21	57.30	6.53
AUC	13.51	9625.77	1096.71

Mefloquine

	Human Prediction PK 1250mg single	Human Prediction PK 250mg-weekly multiple	IC50 in Vero cell	IC50 in Calu-3 cell
Cmax	2.8	1.4	86.3	996.6
AUC	871	1338	138080	1594560

Niclosamide

	Human Prediction PK Rat based model	Human Prediction PK Dog-Rat based model	IC50 in Vero cell
Cmax	0.01	0.04	57.25
AUC	0.98	2.56	9618

Chloroquine

	Human Prediction PK	IC50 in Vero cell	IC50 in Calu-3 cell
Cmax	2.03	9.67	91.81
AUC	224.48	1624.56	15424.08

Spiramycin

	Human Prediction PK	IC50 in Vero cell
Cmax	1.31	6.7
AUC	160.54	1340

Hydroxychloroquine

	Human Prediction PK	IC50 in Vero cell
Cmax	1.51	1.4
AUC	126.43	235.16

Quinidine

	Human Prediction PK	IC50 in Vero cell
Cmax	1.78	1.66
AUC	225.35	278.88

Probenecid

	Human Prediction PK 1 g (q12h)	Human Prediction PK 500 mg (q6h)	IC50 in Vero cell
Cmax	82.8	57.4	0.214
AUC	10651.35	8461.23	42.80

Cyclosporine

	Human Prediction PK	IC50 in Vero cell
Cmax	1.04	7.0
AUC	78.66	1400